Sangamo Therapeutics Inc. (SGMO): Skating on Thin Ice? We Know the Answer – News Heater
Home  »  Companies   »  Sangamo Therapeutics Inc. (SGMO): Skating on Thin ...

Sangamo Therapeutics Inc. (SGMO): Skating on Thin Ice? We Know the Answer

Sangamo Therapeutics Inc. (NASDAQ:SGMO) went up by 10.06% from its latest closing price compared to the recent 1-year high of $12.83. The company’s stock price has collected 20.12% of gains in the last five trading sessions.

Is It Worth Investing in Sangamo Therapeutics Inc. (NASDAQ :SGMO) Right Now?

Plus, the 36-month beta value for SGMO is at 1.54. Opinions of the stock are interesting as 7 analysts out of 11 who provided ratings for Sangamo Therapeutics Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 3 rated it as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


The average price from analysts is $14.49, which is $10.55 above the current price. SGMO currently public float of 121.87M and currently shorts hold a 8.21% ratio of that float. Today, the average trading volume of SGMO was 1.61M shares.

SGMO’s Market Performance

SGMO stocks went up by 20.12% for the week, with a monthly drop of -1.50% and a quarterly performance of -31.83%, while its annual performance rate touched -65.95%. The volatility ratio for the week stands at 8.98% while the volatility levels for the past 30 days are set at 7.95% for Sangamo Therapeutics Inc. The simple moving average for the period of the last 20 days is 6.86% for SGMO stocks with a simple moving average of -41.68% for the last 200 days.

Analysts’ Opinion of SGMO

Many brokerage firms have already submitted their reports for SGMO stocks, with Wedbush repeating the rating for SGMO by listing it as a “Neutral.” The predicted price for SGMO in the upcoming period, according to Wedbush is $5 based on the research report published on June 13th of the current year 2022.

RBC Capital Mkts, on the other hand, stated in their research note that they expect to see SGMO reach a price target of $22. The rating they have provided for SGMO stocks is “Outperform” according to the report published on May 04th, 2021.

Guggenheim gave a rating of “Neutral” to SGMO, setting the target price at $16 in the report published on January 07th of the previous year.

SGMO Trading at -6.29% from the 50-Day Moving Average

After a stumble in the market that brought SGMO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.29% of loss for the given period.

Volatility was left at 7.95%, however, over the last 30 days, the volatility rate increased by 8.98%, as shares sank -4.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.76% lower at present.

During the last 5 trading sessions, SGMO rose by +20.12%, which changed the moving average for the period of 200-days by -61.90% in comparison to the 20-day moving average, which settled at $3.68. In addition, Sangamo Therapeutics Inc. saw -47.47% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at SGMO starting from Markels John, who purchase 6,784 shares at the price of $3.69 back on Jun 03. After this action, Markels John now owns 32,484 shares of Sangamo Therapeutics Inc., valued at $25,029 using the latest closing price.

PARKER H STEWART, the Director of Sangamo Therapeutics Inc., purchase 5,000 shares at $3.60 during a trade that took place back on Jun 01, which means that PARKER H STEWART is holding 48,700 shares at $17,996 based on the most recent closing price.

Stock Fundamentals for SGMO

Current profitability levels for the company are sitting at:

  • -165.61 for the present operating margin
  • +91.47 for the gross margin

The net margin for Sangamo Therapeutics Inc. stands at -161.05. Equity return is now at value -45.20, with -23.60 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 3.12.

Is Kimberly-Clark Corporation (KMB) a Keeper?

Kimberly-Clark Corporation (NYSE:KMB) went up by 3.54% from its latest closing price compared to the recent 1-year high of $145.79. The company’s stock price has